Coral Laboratories Limited's Board of Directors convened on April 2, 2026, at the company's registered office in Mumbai to approve key governance decisions. The meeting, which commenced at 12:03 p.m. and concluded at 12:19 p.m., focused on the re-appointment of an Independent Director and the approval of the postal ballot process for shareholder approval.

Independent Director Re-appointment

The board has approved the re-appointment of Mr. Malay Doshi (DIN: 09186000) as an Independent Director for his second consecutive term. The appointment was made based on the recommendation of the Nomination and Remuneration Committee and is subject to member approval.

The board has confirmed that Mr. Malay Doshi is not debarred from holding office as Director by virtue of any SEBI Order or any other authority, as required under BSE Circular no. LIST/COMP/14/2018-19 and NSE Circular NSE/CML/2018/24.

Director Profile and Qualifications

Mr. Malay Doshi brings extensive professional expertise to the board as the owner of the proprietary firm Malay Doshi & Associates since April 2012. His firm has evolved into a renowned professional organization offering comprehensive services to clients ranging from individuals to large corporates.

The company has disclosed that Mr. Doshi is not related to any directors, Key Managerial Personnel, or promoters of the company.

Postal Ballot and Governance Process

To facilitate shareholder approval for the re-appointment, the board has approved the issuance of a Notice of Postal Ballot and E-voting. The governance framework ensures compliance with regulatory requirements.

Meeting Details and Compliance

The board meeting was conducted at the company's registered office located at 3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (W), Mumbai- 400086. All decisions were made in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has provided the required disclosures in the format prescribed under Regulation 30 read with Schedule III of the SEBI Listing Regulations and SEBI Master Circular dated January 30, 2026. The meeting outcome was communicated to BSE Limited under scrip code 524506.

Coral laboratories has successfully completed the capacity expansion of its General Pharmaceuticals Formulation unit at its Dehradun plant. The company announced on March 23, 2026, that the expansion project has been completed and commercial operations have commenced at the enhanced facility.

Capacity Expansion Details

The expansion project focused on the General Pharmaceuticals Formulation (Ointment) unit at the Dehradun manufacturing facility. The key parameters of the completed expansion include:

Project Timeline and Implementation

The capacity expansion project was initially announced by the company on October 13, 2025. The successful completion of the project within approximately five months demonstrates the company's execution capabilities in scaling its manufacturing operations.

Commercial Operations Commencement

Coral Laboratories confirmed that the expanded facility has commenced commercial operations, indicating that the enhanced production capacity is now contributing to the company's manufacturing output. The operational commencement marks the successful transition from the expansion phase to active production at the increased capacity levels.

Strategic Manufacturing Enhancement

The completion of this capacity expansion represents a significant enhancement to Coral Laboratories' manufacturing capabilities in the pharmaceutical formulation segment. The expanded ointment production capacity of 360,000 kgs positions the company to meet increased market demand and strengthen its presence in the General Pharmaceuticals Formulation category.